ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: When the CML group was divided into two subgroups based on BCR::ABL1 IS levels (≤0.0032% and >0.0032%, <1%), there were no statistically significant differences between the two groups in terms of the treatment duration, use of TKIs, or EUTOS long-term survival (or ELTS) scores.